Clinical Trial Update: Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and immunogenicity of Takeda's Norovirus Bivalent Virus-Like Particle Vaccine in healthy adults; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection

Drugs mentioned

• Norovirus Bivalent Virus-Like Particle Vaccine (Norovirus Bivalent Virus-Like Particle Vaccine)

Snippet

Sponsor: Takeda | Conditions: Norovirus Prevention | Phase 2 | Status: COMPLETED | Results posted: 2017-02-23